152 related articles for article (PubMed ID: 10600600)
1. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.
Barnett JM; Cadman A; Burrell FM; Madar SH; Lewis AP; Tisdale M; Bethell R
Virology; 1999 Dec; 265(2):286-95. PubMed ID: 10600600
[TBL] [Abstract][Full Text] [Related]
2. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
[TBL] [Abstract][Full Text] [Related]
4. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL
Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997
[TBL] [Abstract][Full Text] [Related]
5. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro.
Baigent SJ; Bethell RC; McCauley JW
Virology; 1999 Oct; 263(2):323-38. PubMed ID: 10544106
[TBL] [Abstract][Full Text] [Related]
9. Zanamivir: from drug design to the clinic.
Elliott M
Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
[TBL] [Abstract][Full Text] [Related]
10. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.
Blick TJ; Tiong T; Sahasrabudhe A; Varghese JN; Colman PM; Hart GJ; Bethell RC; McKimm-Breschkin JL
Virology; 1995 Dec; 214(2):475-84. PubMed ID: 8553549
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
14. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
Aoki FY; Hayden FG
Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
[No Abstract] [Full Text] [Related]
15. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
Taylor NR; Cleasby A; Singh O; Skarzynski T; Wonacott AJ; Smith PW; Sollis SL; Howes PD; Cherry PC; Bethell R; Colman P; Varghese J
J Med Chem; 1998 Mar; 41(6):798-807. PubMed ID: 9526556
[TBL] [Abstract][Full Text] [Related]
18. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.
Jackson D; Barclay W; Zürcher T
J Antimicrob Chemother; 2005 Feb; 55(2):162-9. PubMed ID: 15665027
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
20. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]